Technologies

New Inventions

New and More Potent UGM Inhibitors for Treating Tuberculosis, Other Microbial Infections

UW–Madison researchers have developed a new set of UGM inhibitors to fight tuberculosis and other diseases caused by microbial infections. The compounds feature an N-acylsulfonamide motif and are more potent in vitro than inhibitors previously identified by the researchers.
(Mar 13, 2017) P160093US02

Compound Combination Targets Bacterial Virulence

The researchers have discovered that two lead compounds (E22/M64) can be combined to target multiple QS pathways at the same time (Rhl/Pqs), resulting in enhanced activity against P. aeruginosa and potentially other pathogens. This new cocktail approach is superior because it attenuates virulence factor production across a range of relevant environments where single compounds fail.
(Feb 13, 2017) P160176US02

Inhibiting Metadherin/SND1 Interaction to Treat Cancer

UW–Madison researchers and collaborators have developed a method to fight tumor growth and metastasis using novel peptides that inhibit interaction between MTDH and a protein called SND1.

The researchers found that MTDH-SND1 protein interaction is important for the expansion and function of prostate tumors as well as luminal and basal breast tumor initiating cells. Their work provides novel peptides that target this protein complex to help control tumor initiation, recurrence and metastasis by combating tumor initiating cells, with minimal impact on normal tissues.
(Dec 22, 2016) P140424US02

Nylon-3 Polymers to Treat Fungal Infections

UW–Madison researchers have found that nylon-3 polymers developed in their lab display potent antifungal activity against a broad spectrum of common fungal pathogens, with minimal toxicity towards mammalian cells. The polymers have some activity alone, and when used in combination with existing drugs provide synergistic effects against Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus strains, including some resistant strains.

Synergistic combination offers efficacy with significantly reduced amounts of drug and corresponding toxicity, which could potentially expand the relevant patient population.

The polymers were designed to resemble host-defense peptides (HDPs), which are natural molecules that exhibit antimicrobial activities.
(Dec 21, 2016) P170021US01

Monomeric Fluorescent Protein-Ligand Complexes with Strong Fluorescence in the Far-Red Region

Research from the University of Wisconsin-Washington County in collaboration with the Institute for Stem Cell Biology and Regenerative Medicine in India, has resulted in the development of monomeric variants of the naturally occurring Sandercyanin Fluorescent Protein (SFP) using site-directed mutagenesis. This work has stemmed from earlier research focused on development of the tetrameric form of SFP, a biliverdin-binding lipocalin protein originally isolated from the mucus of the blue walleye fish, Sander vitreus. Monomeric variants of SFP (mSFPs) have been found to possess the same non-covalent, bili-binding characteristics of the tetramer but are one-quarter the size (~18.6kDa) and do not oligomerize. They are therefore anticipated to be more useful in a host of biotechnology applications. Like the tetrameric form, the mSFPs have a large stokes shift (375nm/675nm) and fluoresce in the far-red or near infrared region, which is advantageous for a wide range of applications including investigation of protein-protein interactions, spatial and temporal gene expression, assessing cell biology distribution and mobility, studying protein activity and protein interactions in vivo, as well as cancer research, immunology, and stem cell research and sub-cellular localization. In addition, the newly developed mSFP’s far-red fluorescence is particularly advantageous for in vivo, deep-tissue imaging.
(Dec 20, 2016) T150029WO01

Modified Cyanobacteria for Competitive Sugar Production

UW–Madison researchers have developed strains of Synechococcus sp. Strain PCC 7002 with the highest reported glycogen or starch production rate of any cyanobacteria or algae. The strains are genetically modified to overexpress a glucose-1-phosphate adenylyltransferase.
(Dec 1, 2016) P160039US02

Retinoic Acid: A New Treatment for Sleep Apnea and Hypopnea

UW–Madison researchers have developed a new method for treating sleep apnea and hypopnea with retinoic acid.

A patient can be given a retinoid or retinoic acid receptor agonist such as all-trans RA (ATRA), 13-cis RA (isotretinoin) or 9-cis RA (alitretinoin). These compounds target the mechanisms that cause sleep apnea in two ways. First, they increase the respiratory drive (urge to breathe). Additionally, they reduce the apneic threshold (the level of CO2 necessary for the induction of breath) to normal levels.
(Oct 13, 2016) P150330US02

Improved System for Stroke Therapy and Rehabilitation

UW-Madison researchers have developed an improved system for stroke therapy and rehabilitation.  This system collects movement intention signals from the brain in real-time via EEG and initiates functional electrical stimulation (FES) of the appropriate muscle(s) to assist the neurons in regrowing their connections from the brain to the muscles along the correct pathways.  Additional general sensory stimulation may be added to this therapy to further encourage proper neuron regrowth. 
(Oct 10, 2016) P09245US02

Building Framing System with Innovative Snap-in Track for Residential and Commercial Construction

An inventor who is an alumnus of UW-Fond du Lac has developed a building framing system for fast and easy construction of interior non-load-bearing walls. The unique design of the system allows a series of studs to be temporarily secured without fasteners, until sheetrock or other face material can be applied. The system does not need to be secured against sidewalls, and can accommodate both wood and metal studs, which can easily be removed and adjusted as needed. The system is flexible and can secure studs that vary in length by up to ½”. This technology offers a user-friendly tool for experienced construction professionals or for home improvement projects such as do-it-yourself basement finishing.
(Sep 28, 2016) T160038US01

Treatment of Fragile X Syndrome Using Nutlin-3

UW–Madison researchers have discovered that Nutlin-3, a candidate antitumor drug, and its derivatives may be useful for treating patients with FXS or other intellectual disability. This is the first time that Nutlin-3 has been shown to inhibit adult neural stem cell proliferation and rescue cognitive deficits in a FXS mouse model.

Nutlin-3 is a small molecule MDM2-p53 pathway inhibitor developed in 2004. The researchers use <10x dosage for FXS compared to the dosage used for cancer treatment.
(Sep 23, 2016) P150380US02